ストックスクリーナーアプリを入手
1.57
4.27%
-0.07
プレマーケット:
1.59
0.02
+1.27%
前日終値:
$1.64
開ける：
$1.63
24時間の取引高:
265.88K
Relative Volume:
0.57
時価総額：
$26.31M
収益：
-
当期純損益:
$-40.94M
株価収益率:
-0.4089
EPS:
-3.84
ネットキャッシュフロー:
$-22.97M
1週間 パフォーマンス:
+28.69%
1か月 パフォーマンス:
-20.30%
6か月 パフォーマンス:
-84.09%
1年 パフォーマンス:
-88.46%
1日の値動き範囲:
$1.49
$1.64
1週間の範囲:
$1.21
$1.7083
52週間の値動き範囲:
$1.11
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.57 | 26.31M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada
Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com
Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Buntanetap for Parkinson’s disease - Parkinson's News Today
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India
Annovis Bio Receives Non-Compliance Notice from NYSE - MSN
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN
Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa
Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener
Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks
Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire
NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire
Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq
Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan
Annovis Bio Inc. (ANVS) reports earnings - Quartz
Annovis Bio, Inc. SEC 10-K Report - TradingView
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Annovis Bio Inc. Reports Corporate Updates and Financial Results for Fourth Quarter and Full Year 2024 - Nasdaq
Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com Australia
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire
Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia
ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire
Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):